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hazard ratios from a large trial with up to 28 years of follow-up
(Nordestgaard et al. 2007). This analysis used baseline lipid
proﬁle and lipid efﬁcacy data from three 12-week fenoﬁbric acid
(FA)/statin studies, where FA 135 mg combinedwith atorvastatin,
rosuvastatin, and simvastatin at low (20 mg, 10 mg, 20 mg,
respectively) and moderate (40 mg, 20 mg, 40 mg, respectively)
doses was compared to FA and corresponding statinmonotherapy
doses. RESULTS: Compared to statin monotherapy, combination
of FA 135 mg with low-dose simvastatin, rosuvastatin and ator-
vastatin was predicted to reduce 3-year CVE rates by 30% (from
35 to 27 events), 32% (from 33 to 25), and 33% (from 40 to 27),
respectively. Predicted 3-year CVE reductions were 15% to 21%
for FA in combination with a moderate-dose statin compared to
corresponding statin monotherapy. CONCLUSIONS: Patients
with multiple lipid abnormalities may require additional treat-
ment beyond statin monotherapy to address their dyslipidemia.
This analysis suggests that treatment with FA 135 mg in combi-
nation with a statin may result in a greater reduction in CVEs than
treatment with statin monotherapy.
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OBJECTIVES: Several reports have already proved that the
number of deaths related to acute myocardial infarction (AMI)
shows a seasonal variation, with a peak in winter, and a lowest
rates during the months of summer. The effects of meteorological
variables on the human organism have been studied for more
than ﬁfty years, and changes in the number of AMI events have
been related to both cold or warm temperatures. METHODS:
The number of cardiac mortality (N = 16.160) in Hungary shows
a steadily decreasing tendency between 2000 and 2005, with a
seasonal variation regardless of age or sex. RESULTS: The peak
period of AMI mortality was during the months of spring, with
a lowest value during the summer. There was a signiﬁcant differ-
ence between seasons (F = 3.027; p < 0.05). The daily average of
cardiovascular mortality during each season was the following:
8.48 during spring, 7.23 during the summer, 7.79 during
autumn, and 7.76 during winter. The sharp temperature increase
during spring, and the similarly signiﬁcant decrease of tempera-
tures during autumn, both have an increasing effect on heart
attack related mortality. Studying the moving-average of AMI
mortality (k = 7), and the relation with the daily average tem-
perature of the preceding 7 days, we have found a medium value
negative correlation (r = -0.466, p < 0.01). Considering the
moving average of deaths (k = 7) and the average daily tempera-
ture of the preceding seven days above and below 20 Celsius, we
have found a signiﬁcant difference. CONCLUSIONS: The mor-
tality of AMI may be related to the internal biological rhythm of
the organism, and also to such external conditions as weather.
The combined effect of certain meteorological factors, such as a
sudden temperature or atmospheric pressure change, may be
considered as a risk factor in the mortality of a heart attack.
PCV22
TOLERABILITY OF ROSUVASTATIN 40 MG COMPAREDTO
20 MG INTHETREATMENT OF HYPERCHOLESTEROLAEMIA:
EVIDENCE FROM RANDOMISED CONTROLLEDTRIALS
Edwards SJ, Kingslake SL
AstraZeneca UK Ltd, Luton, UK
OBJECTIVES: To compare the tolerability of rosuvastatin 40 mg
with 20 mg in the treatment of patients with hypercholestero-
laemia based on a meta-analysis of 9 randomised controlled trials
(n = 3314) from the CRESTOR clinical trial programme.
METHODS: Data were extracted on the following organ
systems: Muscle (rhabdomyolysis, myopathy, myalgia, creatine
kinase increase); Liver (liver failure, hepatitis, abnormal liver
function [ALT increase]); Renal (renal failure, serum creatinine
increase, haematuria, proteinuria). The events analysed were all
treatment-emergent adverse events rather than treatment-related
adverse events to provide an objective evaluation of any possible
difference in risk between rosuvastatin 40 mg and 20 mg.
Summary effect estimates were calculated as risk difference (RD)
in meta-analyses using a ﬁxed effects model. RD is an absolute
measure of the difference in tolerability, i.e. percentages reported
are the risk of an event with rosuvastatin 40 mg compared to
20 mg (positive values indicate higher, negative values lower).
RESULTS: The event rates were low for all outcomes. For rhab-
domyolysis, liver failure, and hepatitis there were no events
with either rosuvastatin 40 mg or 20 mg. Other outcomes had
the following results—Muscle: myopathy 0.006% (95%CI:
-0.266% to 0.279%, p = 0.963), myalgia 0.216% (95%CI:
-0.874% to 1.306%, p = 0.697), creatine kinase increase
0.424% (95%CI: -0.099% to 0.947%, p = 0.112); Liver: abnor-
mal liver function 0.189% (95%CI: -0.415% to 0.793%,
p = 0.540); Renal: renal failure -0.023% (95%CI: -0.296% to
0.251%, p = 0.871), serum creatinine increase 0.033% (95%CI:
-0.239% to 0.305%, p = 0.811), haematuria -0.015%
(95%CI: -0.372% to 0.342%, p = 0.936), proteinuria 0.070%
(95%CI: -0.274% to 0.415%, p = 0.689). Sensitivity analysis,
using random effects model, demonstrated no difference in any of
the outcomes except myalgia, for which there was a small
numerical difference (0.420%; 95%CI: -1.332% to 2.172%;
p = 0.638). CONCLUSIONS: There is no evidence from ran-
domised controlled trials to suggest any difference in tolerability
between rosuvastatin 40 mg and 20 mg.
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